E-five registry: To evaluate the 'real world' clinical performance of the Medtronic Endeavor ABT-578 [zotarolimus] eluting coronary stent system; a prospective, multicenter registry

Trial Profile

E-five registry: To evaluate the 'real world' clinical performance of the Medtronic Endeavor ABT-578 [zotarolimus] eluting coronary stent system; a prospective, multicenter registry

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Nov 2015

At a glance

  • Drugs Zotarolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Adverse reactions; Registrational
  • Acronyms ENDEAVOR-Five
  • Most Recent Events

    • 15 Dec 2011 Actual end date (February 2009) added as reported by ClinicalTrials.gov.
    • 15 Dec 2011 Actual end date (February 2009) added as reported by ClinicalTrials.gov.
    • 15 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top